Idarubicin Phares (Idarubicin Hydrochloride)

Idarubicin intercalates between DNA base pairs and inhibits the enzyme topoisomerase II, preventing the resealing of DNA strands during replication. This action creates double‑strand breaks, triggers apoptosis, and preferentially affects rapidly proliferating cancer cells, thereby reducing leukemic burden.

The specific dose and schedule of Idarubicin Phares are determined by the treating physician based on the patient’s diagnosis, disease stage, body surface area, and overall health. Clinicians calculate the appropriate intravenous infusion regimen and adjust it according to therapeutic response and tolerability.

Safety data for idarubicin in pregnancy and lactation are limited, and the drug is generally considered contraindicated because of its potential to cause fetal toxicity and adverse effects on the newborn. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their oncologist.

To place an order, submit an enquiry on the Idarubicin Phares product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Compared with doxorubicin, idarubicin is more lipophilic, allowing greater cellular uptake and potentially higher antitumor activity at equivalent doses. It also exhibits a slightly different toxicity profile, with a lower incidence of certain cardiac effects but similar risks of myelosuppression. Choice of agent depends on clinical judgment, disease characteristics, and patient‑specific factors.

Idarubicin Phares should be stored in a refrigerator at 2 °C to 8 °C, protected from light, and kept in its original container to maintain stability. The product must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended storage period.

Idarubicin Phares is given by intravenous infusion, typically over a period of 30 minutes to several hours, depending on the prescribed protocol. Administration is performed in a clinical setting by qualified healthcare professionals, with appropriate monitoring of vital signs and cardiac function before, during, and after the infusion.

The most serious adverse risks include cardiotoxicity, which can lead to irreversible heart failure; severe myelosuppression resulting in life‑threatening infections or bleeding; and rare secondary malignancies such as therapy‑related leukemia. Patients should be closely monitored for cardiac function, blood counts, and any signs of infection throughout treatment.

Idarubicin Phares is contraindicated in patients with known hypersensitivity to idarubicin or other anthracyclines, those with pre‑existing severe cardiac disease, uncontrolled infections, or significant hepatic impairment. It should also be avoided in pregnant or nursing women unless no safer alternative exists and the potential benefits outweigh the risks.